Mark Dearden Named Chief Executive Officer Of Specac, Ltd

ORPINGTON, England, July 2, 2024 /PRNewswire/ -- Specac, Ltd ("Specac"), a global leader in the design and manufacture of spectroscopy accessories and sample prep solutions and an Ampersand Capital Partners ("Ampersand") portfolio company, is pleased to announce the appointment of Mark Dearden to its Board of Directors as President and Chief Executive Officer (CEO), effective July 1, 2024.

Mr. Dearden is a seasoned international executive with over 30 years of experience in the life sciences industry dedicated to scientific innovation and impactful outcomes. Upon joining the LGC Group in 2011, Mr. Dearden served as Vice President of Strategy and Marketing for the Genomics Division before being appointed its Managing Director in July 2020. Prior to LGC, Mr. Dearden held various international leadership positions in general management, marketing, product management, and sales with leading life sciences companies such as Amersham Biosciences, GE Healthcare and Thermo Electron. Mr. Dearden holds a Bachelor of Science with Honors from the University of Sydney and an MBA from Warwick Business School.

Upon his appointment as CEO, Mr. Dearden commented, "I am honored and thrilled to have the privilege of leading the teams at Specac and its recently acquired Harrick division. I believe the combined company has tremendous opportunities to build on its strong product portfolio, global distribution reach and loyal customer base. I look forward to leading the company through its next phase of growth by leveraging these strengths and accelerating product innovation."

Dave Patteson, an Ampersand Partner, added, "Mark brings substantial, global experience from the pharmaceutical, diagnostics and applied research market sectors. As a seasoned executive, we are excited about the contributions Mark will make as CEO to lead Specac's ambitious growth strategy and drive value creation for all its stakeholders."

About Specac, Ltd.

Specac and its Harrick division design and manufacture Fourier Transform Infrared (FTIR) accessories, Sample Preparation/XRF, Process Cells, and IR polarizer products for atomic and molecular spectroscopy. These products include ATR accessories, specular reflectance accessories, diffuse reflectance accessories, liquid transmission and gas transmission cells, as well as infrared and terahertz wire grid polarizers, bench-top hydraulic presses, KBr pellet presses, XRF pellet presses, thin film-making kits and evacuable pellet dies. For online optical spectroscopy or FTIR analysis, Specac offers a comprehensive range of NIR Process Cells suitable for liquid and gas/vapor analysis. Learn more at specac.com.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. For additional information, visit www.ampersandcapital.com or follow us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mark-dearden-named-chief-executive-officer-of-specac-ltd-302187557.html

SOURCE Specac, Ltd

First published on Tue, Jul 2, 2024

Liked what you read? That’s only the tip of the tech iceberg!

Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!

Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.

Dive into TechDogs' treasure trove today and Know Your World of technology like never before!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

Specac Ltd. Ampersand Capital Partners Fourier Transform Infrared (FTIR) Assets Under Management Life Sciences

Join The Discussion

- Promoted By TechDogs -

Hiring